Please turn JavaScript on
Homepage
TrendingMy newsFind FeedsDelivery settingsPlansMy earnings
HelpBlog
Log in
Find more feeds

Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals.

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  1.33 / day

Message History

GLP-1s and Thyroid Safety in 2026: What Do Human Data Show?

GLP-1 receptor agonists have transformed diabetes and obesity treatment, yet safety questions still surface in clinic visits. One concern continues to appear in patient discussions: thyroid cancer risk. The topic often traces back to early rodent studies that triggered boxed warnings for medullary thyroid carcinoma (MTC). However, clinicians today rely on a growing body of


Read full story
GLP-1s and Rapid A1C Reduction: Should We Be Monitoring Retinopathy More Closely?

GLP-1 receptor agonists and dual incretin therapies are transforming diabetes care. These medications often produce significant and rapid improvements in glycemic control, sometimes lowering A1C levels faster than traditional treatments. However, clinicians have begun asking an important question: could rapid A1C reduction with GLP-1 therapy increase retinopathy risk<...


Read full story
Reassessing Hypoglycemia Risk in the Era of Modern Therapies

Managing the risk of hypoglycemia remains a central challenge in diabetes care, even as newer therapies lower the rate of severe events. Although GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment strategies, insulin and sulfonylureas are still widely used, especially among older adults and patients with chronic kidney disease (CKD). As a result, clinicians ...


Read full story
Time in Range in 2026: Moving From Metric to Treatment Target

Continuous glucose monitoring has transformed diabetes care, but are we fully using the data it provides? In 2026, time in range is moving beyond a simple CGM metric and becoming a formal therapeutic target in diabetes care. While A1C remains important, time in range (TIR) offers a more dynamic and patient-centered view of glycemic control. As technology becomes routine in bo...


Read full story
Early Combination Therapy in Type 2 Diabetes: Is Monotherapy Becoming Obsolete?

When managing type 2 diabetes, should clinicians still begin with one medication and wait for treatment failure before intensifying therapy? Increasingly, evidence suggests that early combination therapy in type 2 diabetes may provide better durability, faster glycemic control, and improved cardiovascular and kidney outcomes in high-risk patients. While metformin monotherapy ...


Read full story